Novo Nordisk A/S - NVO Stock Forecast, Price & News

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View NVO analyst ratings or view top-rated stocks.

19 equities research analysts have issued 1 year target prices for Novo Nordisk A/S's shares. Their NVO share price forecasts range from $130.00 to $900.00. On average, they anticipate the company's stock price to reach $682.43 in the next twelve months. This suggests a possible upside of 552.7% from the stock's current price.
View analysts price targets for NVO or view top-rated stocks among Wall Street analysts.

Novo Nordisk A/S's stock was trading at $112.00 at the beginning of the year. Since then, NVO stock has decreased by 6.7% and is now trading at $104.55.
View the best growth stocks for 2022 here.

Novo Nordisk A/S saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,310,000 shares, an increase of 26.0% from the July 15th total of 1,040,000 shares. Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.1% of the shares of the company are sold short.
View Novo Nordisk A/S's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our NVO earnings forecast.

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings results on Tuesday, November, 2nd. The company reported $5.27 EPS for the quarter, beating analysts' consensus estimates of $0.78 by $4.49. The firm had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.64 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 72.10% and a net margin of 32.14%.

Novo Nordisk A/S declared a semi-annual dividend on Friday, August 5th. Investors of record on Monday, August 15th will be paid a dividend of $0.5836 per share on Tuesday, August 23rd. This represents a dividend yield of 1.1%. The ex-dividend date is Friday, August 12th.
Read our dividend analysis for NVO.

Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $0.81 per share and currently has a dividend yield of 0.79%. The dividend payout ratio is 24.18%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 19.42% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

Novo Nordisk A/S issued an update on its FY 2022 earnings guidance on Friday, August, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $22.59 billion-$23.40 billion, compared to the consensus revenue estimate of $23.52 billion.

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.77%), Jennison Associates LLC (0.46%), Loomis Sayles & Co. L P (0.23%), Folketrygdfondet (0.18%), WCM Investment Management LLC (0.17%) and State Street Corp (0.16%).
View institutional ownership trends.

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVO stock can currently be purchased for approximately $104.55.

Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $236.59 billion and generates $22.40 billion in revenue each year. The company earns $7.60 billion in net income (profit) each year or $3.35 on an earnings per share basis.

The company employs 45,000 workers across the globe.

Novo Nordisk A/S was founded in 1923.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for the company is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at phak@novonordisk.com, or via fax at 45-4449-0555.